论文部分内容阅读
目的分析盐酸司来吉兰联合美多巴对帕金森病患者神经功能及日常活动能力的影响。方法选取2014年6月至2016年7月帕金森病患者70例作为研究对象,将所有患者按照随机数表法分为两组,每组35例。对照组采用单纯美多巴治疗,观察组在美多巴治疗的基础上联合盐酸司来吉兰治疗,对比两组治疗前及治疗后1、3、6个月的临床效果,包括精神状态、运动能力及日常生活能力等三个方面;对比两组不良反应发生率。结果治疗前及治疗后1个月,两组患者精神状态、运动能力及日常生活能力评分比较差异未见统计学意义(P>0.05),治疗后3个月及6个月,观察组患者精神状态、运动能力及日常生活能力评分均小于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异未见统计学意义(P>0.05)。结论与单纯美多巴治疗相比,盐酸司来吉兰联合美多巴可有效改善帕金森病患者的临床症状,同时提高患者的日常活动能力、精神状态及运动能力,且用药安全可靠,在临床应用中具有较高的推广价值。
Objective To analyze the effect of selegiline hydrochloride combined with metopar on the neurological function and daily activities of patients with Parkinson’s disease. Methods Seventy patients with Parkinson’s disease from June 2014 to July 2016 were selected as the research object. All patients were divided into two groups according to the random number table method, with 35 cases in each group. The control group was treated with meridose alone, and the observation group was treated with selegiline hydrochloride on the basis of the treatment of metoparaffin. The clinical effects of the two groups before treatment and 1, 3, and 6 months after treatment were compared, including mental state, Exercise capacity and daily living ability of three aspects; compared two groups adverse reaction rate. Results Before treatment and 1 month after treatment, there was no significant difference in scores of mental status, exercise ability and daily living ability between the two groups (P> 0.05), the patients in observation group at 3 months and 6 months after treatment (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05) .2. Conclusions Selegiline and metoparamin hydrochloride can effectively improve the clinical symptoms of patients with Parkinson’s disease and improve their daily activities, mental status and motor ability as compared with those of mereodopa alone. The medication is safe and reliable. Clinical application has a higher promotional value.